Mednet Logo
CommunityMedical Oncology

How would you treat node positive (pN+) prostate cancer with undetectable post-op PSA after radical prostatectomy and pelvic LND?

Would you offer adjuvant radiation? (Dose? Target?) vs Salvage? Would you add ADT? Would you add abiraterone? Would the number of lymph nodes involved influence your decision?
5 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center
Answered on

The short answer is, YES I would, in general, recommend treatment.

I also respectfully disagree that ADT monotherapy is the standard of care. It is an option of course, but rarely performed given it is non-curative and the data to support its use is of minimal relevance today.

Some key points of reas...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan Kettering Cancer Center
Answered on

Some minor points that might add to the discussion.

Should adjuvant RT be given?

If the vast majority of men with pN+ disease have biochemical recurrence, then do the big randomized trials comparing adjuvant vs early salvage apply? Or should we just wait for PSA to recur and then treat?

While the ARTIS...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Michigan Healthcare Professionals, PC
Answered on

The Messing trial established that these patients should be getting long term ADT (if not life-long), and though it was a small study, ADT dramatically improved survival.

So, the question really is, should you add RT? There is not prospective evidence, however there is a large series (Mayo + Milan) ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network
Answered on

These subsets were not included in all post op studies comparing early salvage vs adjuvant treatment. Published data suggest a high risk of BCR in this subset of node-positive post op patients without any adjuvant treatment. ADT alone is probably not curative. I favor adjuvant RT plus ADT unless pos...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Radiant Oncology
Answered on

@Dr. First Last - What are your thoughts on the addition of Abiretarone to this patient population? The STAMPEDE trial was for intact prostate. Would insurance ever consider coverage for post-RP patients with N+ disease? Thank you!

Join for free or sign in to see the full answer